Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


24. September 2021 | 14:10 CET

BioNTech, Valneva, Defence Therapeutics: New highs for vaccine stocks?

  • Biotechnology
Photo credits: pixabay.com

Investors in COVID-19 vaccine manufacturers have had little reason to rejoice in recent weeks. Top dogs Moderna and BioNTech have come back noticeably from their highs. Valneva's stock plummeted on Monday. Only newcomer Defence Therapeutics has held its ground at a high level. But for all of them, the calm could soon be over, and a new high could begin. Because people in other parts of the world are still not vaccinated. In addition, winter is just around the corner in Western countries, which means that Corona rates are rising. In addition, a new study shows the risk of long-COVID - such as memory and concentration deficits - even in children. With this mix, vaccine stocks face an exciting fall.

time to read: 3 minutes by Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , VALNEVA SE EO -_15 | FR0004056851 , DEFENCE THERAPEUTICS INC | CA24463V1013


 

Author

Fabian Lorenz

For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

About the author


Defence Therapeutics: Vaccine newcomer with attractive valuation

Recent news shows that Corona will be with us for a long time. It is good news for Defence Therapeutics. The Canadians' goal is to develop universal vaccines. To that end, they have developed their proprietary Accum™ technology. On this, Defence Therapeutics is working on vaccines against cancer and infectious diseases - these include COVID-19. The Company has now published an update on the development status of the second-generation "non-injectable" COVID vaccine, AccuVAC-IN002, for intranasal administration. In doing so, the researchers emphasize that individuals infected with the Delta strain have a viral load in their nasal cavity that is 1260 times higher compared with the original version of the coronavirus. The last point is extremely important, he said, because current vaccination strategies do not provide protection against this airborne transmission of the virus to the mucosal areas that form the initial site of infection. That means vaccinated individuals can still become infected and develop potentially life-threatening symptoms. That is where Defence Therapeutics' vaccine comes in.

"Defence's new AccuVAC-IN002 formulation enables us to elicit both IgA and IgG antibody responses at the systemic level and mucosal sites. This would have the effect of blocking transmission, thus not only stopping the initial infection but also ensuring nearly 100% blockage of viral release (shedding)," explained Mr. Plouffe, CEO of Defence Therapeutics. "In addition, our new AccuVAC-IN002 formulation can be further developed to function as a "universal" vaccine capable of targeting 4 to 8 strains simultaneously, which would provide effective protection against all known variants and future emerging strains," he added. In addition, he said, the current progression of the SARS-COVID virus suggests that it will evolve into a new influenza-like seasonal virus. Accordingly, vaccination would be needed every 6 to 12 months.

Defence Therapeutics is currently valued at "only" around EUR 170 million. This valuation seems attractive, especially given Valneva's EUR 1.3 billion. While Valneva is already further along in development, if Defence Therapeutics' platform strategy is successful, it should produce a whole series of vaccines.

Valneva: Recovered from the shock?

Keyword Valneva. The share seems to have recovered from the shock at the start of the week. On Monday, the UK government's surprise termination of the supply contract for the Company's COVID-19 vaccine, which is currently under development, resulted in a price slide of over 40%. The canceled supply contract for the classic inactivated vaccine was worth USD 1.4 billion. However, investors now seem to have regained their courage. The Valneva share has gained up to 25% in recent trading days. It has thus broken away from the chart-technically important 200-day line to the upside. Analysts also continue to be optimistic. Goldman Sachs recommends the Valneva share with a price target of EUR 14.50 as a buy. The analysts at Kepler Cheuvreux also believe in the Company's success. They name a price target of EUR 24 and also recommend the share as a buy. Whether the share can make sustained gains will depend on the study results.

BioNTech: Consolidation over?

BioNTech shareholders needed patience in recent weeks. The high in August of around EUR 400 is far behind, and the share is consolidating - with partly high fluctuations - around EUR 300. However, the environment is right. Together with its partner Pfizer, the Company is working on the approval of the vaccine for children. According to both companies, test subjects between the ages of five and eleven have tolerated the active ingredient well. The vaccine elicited a stable immune response, they said. In order to speed up the approval process, the results have already been sent to the relevant authorities in the USA and Europe. Approval could therefore be granted in just a few weeks. There is further positive news from the USA. US President Biden has announced that the country will donate 500 million more vaccine doses to poorer countries. The doses will be ordered from BioNTech/Pfizer. That brings the total US donation commitments to 1.1 billion doses.


As summer comes to an end, vaccine stocks could be poised for a new high. Top dog BioNTech is a base investment in the sector. Defence Therapeutics is still a long way from approval but is also not widely unknown and attractively valued. Valneva, which is still valued at EUR 1.3 billion, will rise and fall with the upcoming trial results.


Author

Fabian Lorenz

For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. October 2021 | 11:04 CET | by Armin Schulz

Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?

  • Biotechnology

The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.

Read

18. October 2021 | 10:44 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Bayer: Where triple-digit returns beckon

  • Biotechnology

The pandemic is drawing to a close. Vaccination rates are high, and a new wave is - fortunately - not picking up speed. But in this environment, what is happening to many highly acclaimed pandemic stocks? Are vaccine manufacturers still interesting at the moment? We look at how the industry is faring and where opportunities can still be found.

Read

14. October 2021 | 11:27 CET | by André Will-Laudien

BioNTech, Cardiol Therapeutics, CureVac: A decade's worth of ideas!

  • Biotechnology

Biotechnology remains a hotly contested industry. In the fight against a wide range of diseases, biopharmaceuticals are the first port of call. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. By directly applying findings from biology and biochemistry, technically functional elements are identified. The central objectives are to research, improve and develop processes for the production of relevant substances. Often research goes nowhere; we take a look at the sector.

Read